JPRN-jRCT2080224528已完成3 期
Phase 3 Study of SK-1403
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Serum PTH>240 pg/mL at the screening
- •-Serum corrected Ca>=8.4 mg/dL at the screening
- •-Stable chronic kidney disease patients who undergo hemodialysis or hemodialysis filtration
排除标准
- •-Primary hyperparathyroidism
- •-Severe liver disease
- •-Severe Cardiac disease
- •-History or family history of long QT syndrome
- •-Malignant tumor
- •-Uncontrolled diabetes mellitus
- •-Uncontrolled hypertension
- •-History of severe drug allergy
研究者
相似试验
未知
3 期
Phase 3 study of K-133WDysmenorrheaJPRN-jRCT1080220756Kowa Co., Ltd.
未知
3 期
TK-641 Phase 3 StudyJPRN-jRCT2080221351TEIKOKU SEIYAKU CO., LTD.
未知
3 期
KD-357 Phase III Studypreexposure prophylaxis against rabiesJPRN-jRCT2080222145The Chemo-Sero-Therapeutic Research Institute200
进行中（未招募）
1 期
Study of first administration in humans and efficacy of NMS-03592088, an inhibitor of FLT3, KIT and CSF1R, in patients with Relapsing or Drug-resistant Acute Myeloid Leukemia (LMA) and Chronic Myelomonocytic Leukemia (LMMC).EUCTR2018-002793-47-ITERVIANO MEDICAL SCIENCES SR165
进行中（未招募）
1 期
A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMMAcute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia(CMML) relapsed or refractoryCTIS2023-508655-39-00erviano Medical Sciences S.r.l.168